PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20389030-6 2010 By Western blotting analysis, we observed decreased intracellular levels of VEGF and HIF-1alpha under octreotide, rapamycin and LY294002. Sirolimus 114-123 vascular endothelial growth factor A Rattus norvegicus 76-80 20389030-4 2010 Octreotide and rapamycin induced a significant decrease in VEGF production by all three cell lines; LY294002 significantly inhibited VEGF production by STC-1 and INS-r3 only. Sirolimus 15-24 vascular endothelial growth factor A Rattus norvegicus 59-63 20389030-7 2010 For rapamycin and LY294002, this effect was likely mediated by the inhibition of the mTOR/HIF-1/VEGF pathway. Sirolimus 4-13 vascular endothelial growth factor A Rattus norvegicus 96-100 20389030-9 2010 In conclusion, our study points out to the complex regulation of VEGF synthesis and secretion in neoplastic GEP endocrine cells and suggests that the inhibition of VEGF production by octreotide and rapamycin may contribute to their therapeutic effects. Sirolimus 198-207 vascular endothelial growth factor A Rattus norvegicus 164-168 17804674-4 2007 Immunohistochemistry showed that sirolimus attenuated the increased expression of renal vascular endothelial growth factor (VEGF), as well as the expression of VEGF receptors 1 and 2. Sirolimus 33-42 vascular endothelial growth factor A Rattus norvegicus 160-164 17804674-5 2007 In conclusion, sirolimus halted the progression of proteinuria and structural damage in a rat model of reduced renal mass, possibly through a reduction in renal VEGF activity. Sirolimus 15-24 vascular endothelial growth factor A Rattus norvegicus 161-165 16539626-0 2006 Rapamycin attenuates liver graft injury in cirrhotic recipient--the significance of down-regulation of Rho-ROCK-VEGF pathway. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 112-116 17384960-12 2007 CONCLUSION: Experimentally, our data show that sirolimus impairs wound healing, and this is reflected by diminished expression of VEGF and nitric oxide in the wound. Sirolimus 47-56 vascular endothelial growth factor A Rattus norvegicus 130-134 16539626-10 2006 In conclusion, rapamycin attenuated graft injury in a cirrhotic rat liver transplantation model by suppression of hepatic stellate cell activation, related to down-regulation of Rho-ROCK-VEGF pathway. Sirolimus 15-24 vascular endothelial growth factor A Rattus norvegicus 187-191 33479328-0 2021 Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin. Sirolimus 99-108 vascular endothelial growth factor A Rattus norvegicus 22-26 11834720-9 2002 Moreover, the stress-mediated induction of HIF-1alpha and VEGF was suppressed by gadolinium (a stretch-activated channel inhibitor), wortmannin, and rapamycin (a FRAP inhibitor). Sirolimus 149-158 vascular endothelial growth factor A Rattus norvegicus 58-62 34381142-6 2021 VEGF-A, VEGF receptor 2, and the co-receptor Neuropilin-1 were upregulated by Rapamycin within 7 days. Sirolimus 78-87 vascular endothelial growth factor A Rattus norvegicus 0-6 35366690-9 2022 RESULTS: The autophagy agonist rapamycin reduced the lesion size, the microvessel density, and VEGF expression, and promoted the production of autophagosomes and the expression of autophagy-related proteins, while the autophagy inhibitor chloroquine had the opposite effects. Sirolimus 31-40 vascular endothelial growth factor A Rattus norvegicus 95-99 34064854-11 2021 Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 235-267 34064854-11 2021 Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 269-273 33479328-1 2021 Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells. Sirolimus 44-53 vascular endothelial growth factor A Rattus norvegicus 98-132 33479328-1 2021 Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells. Sirolimus 44-53 vascular endothelial growth factor A Rattus norvegicus 134-138 33479328-8 2021 In rat retina, rapamycin attenuates the diabetes-induced VEGF overexpression, and in cultured Muller cells and HRMECs, inhibits the hyperglycemia-induced boost ROS. Sirolimus 15-24 vascular endothelial growth factor A Rattus norvegicus 57-61 29893708-6 2018 In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1alpha, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group. Sirolimus 39-48 vascular endothelial growth factor A Rattus norvegicus 96-100 31927699-6 2020 In the condition of short-term or long-term hypoxia and serum deprivation, the apoptotic cells in rapamycin-pretreated cells were less, and secretion of HGF, IGF-1, SCF, SDF-1 and VEGF was increased. Sirolimus 98-107 vascular endothelial growth factor A Rattus norvegicus 180-184 27564518-9 2016 Rapamycin improves lysosomal proteolytic activity by improving cathepsin L activity restoring autophagic cargo degradation, and preventing increased VEGF release (P < 0.0001). Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 149-153 28729914-5 2017 Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus. Sirolimus 20-29 vascular endothelial growth factor A Rattus norvegicus 197-231 28729914-5 2017 Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus. Sirolimus 20-29 vascular endothelial growth factor A Rattus norvegicus 233-237 27997905-7 2016 Blocking mTOR by using rapamycin significantly attenuated activities of HIF-1alpha and VEGF signaling pathways. Sirolimus 23-32 vascular endothelial growth factor A Rattus norvegicus 87-91 24186594-6 2013 Rapamycin in a wide range of concentrations (10(-5) to 10(-8) M) induced a slight inhibitory effect on PC12 viability and decreased cell proliferation at the concentration of 10(-5) M. VEGF, endostatin and JV1-36 did not influence the growth of PC12. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 185-189 23229928-0 2013 Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 93-97 23229928-10 2013 Significantly diminished expression of VEGF and VEGFR mRNA and protein was evident in the sirolimus group. Sirolimus 90-99 vascular endothelial growth factor A Rattus norvegicus 39-43 23229928-11 2013 In vitro, sirolimus reduced VEGF production by podocytes (P < 0.05) and inhibited VEGF-induced proliferation of podocytes, endothelial and mesangial cells. Sirolimus 10-19 vascular endothelial growth factor A Rattus norvegicus 28-32 23229928-11 2013 In vitro, sirolimus reduced VEGF production by podocytes (P < 0.05) and inhibited VEGF-induced proliferation of podocytes, endothelial and mesangial cells. Sirolimus 10-19 vascular endothelial growth factor A Rattus norvegicus 85-89 23229928-13 2013 Sirolimus exhibits greater protection against vasculopathy but induces proteinuria; effects are likely to be related to inhibition of VEGF signalling. Sirolimus 0-9 vascular endothelial growth factor A Rattus norvegicus 134-138 22178140-9 2012 Furthermore, pretreatment with rapamycin, a mTOR specific inhibitor, significantly inhibited HIF-1alpha and VEGF protein after HI. Sirolimus 31-40 vascular endothelial growth factor A Rattus norvegicus 108-112